Please login to the form below
UCB’s Mark Bodmer elected to BIA board
Will hold the position for a three-year fixed term
UCB's Mark Bodmer has been elected to the board of UK trade body the BioIndustry Association (BIA).
Bodmer is VP, NewMedicines Therapeutics at UCB, having joined the company in 2012 as head of immunology.
As a board member of the BIA Bodmer will play a role in shaping the policy environment of the UK biotech industry. He will hold the role for three years, starting in January 2015.
Prior to joining UCB Bodmer served as senior VP of immunoinflammation, medicines discovery and development at GlaxoSmithKline.
His background also includes CEO appointments at three start-ups from 1996 to 2007: Hexagen, Lorantis and Biotica.
Featured jobs
-
Account Director
-
Competitive Salary Offered
-
Account Director, Medical Education
-
Salary TBC
-
Business Director
-
Competitive Salary Offered
- Editorial Assistant Medical Education Agency
-
£25, 000 - £26, 000
- Account Manager / Senior Account Manager
-
35, 000-40, 000
-
Account Manager / Account Director
-
Competative
- Technical Manager – Developer and Commercial Excellence, Healthc...
-
Excellent package
-
Medical Writer
-
Salary TBC
- Senior Account Director development role to Business Director, H...
-
Excellent package
-
Associate Director
-
£75, 000-90, 000
- Engagement Expert, Healthcare Brand Communications, London
-
Excellent package
- Senior Account Manager, Rare Diseases – Medical Communications, ...
-
Excellent package
- Global Business Development Director – Health Education
-
excellent commission
-
Senior Medical Writer
-
Salary TBC
-
Senior Account Manager
-
Competitive Salary Offered
Subscribe to our email news alerts
- Pfizer takeover rumour ignites Amarin shares
- Welcome to the Communique Awards - Communiqué Awards 2018
- NICE rejects Novartis migraine treatment Aimovig
- GSK upbeat on its return to oncology market
- AstraZeneca unveils reorg, hires controversial José Baselga as cancer chief
- AZ’s Sean Bohen to exit after business overhaul; report
PMHub
M&F Health
M&F Health is a full service communications agency, dedicated to the health and wellbeing sector. We are an independent amongst...
Latest intelligence
- The UK’s new five-year pricing agreement
- Pharma has agreed to capped growth again - in exchange for uptake promises...
- Digital applications are transforming the market access landscape
- Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....
- Escaping the spin cycle of sub-optimal launch
- ...
Quick links
Infographics
